

Unresectable Hepatocellular Carcinoma

**A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization**

|   |                                     |  |
|---|-------------------------------------|--|
| <b>Trial Status</b><br>Not Yet Recruiting | <b>Trial Runs In</b><br>1 Countries | <b>Trial Identifier</b><br>NCT06503250 ML45337 |
|---|-------------------------------------|--|

The source of the below information is the publicly available website *ClinicalTrials.gov*. It has been summarised and edited into simpler language.

***Trial Summary:***

This is a multicenter, retrospective, observational cohort study to describe the effectiveness and safety of Atezo+Bev plus Transarterial Chemoembolization (TACE) among adult patients with unresectable hepatocellular carcinoma (HCC) in real-world clinical practice in China. Eligible patients diagnosed with unresectable HCC initiating the Atezo+Bev and TACE between 28 October 2020 and 31 December 2023 will be included in this study.

|                                     |                     |
|-------------------------------------|---------------------|
| <b>Hoffmann-La Roche</b><br>Sponsor | <b>N/A</b><br>Phase |
|-------------------------------------|---------------------|

**NCT06503250 ML45337**  
Trial Identifiers

***Eligibility Criteria:***

|                      |                         |                                 |
|----------------------|-------------------------|---------------------------------|
| <b>Gender</b><br>All | <b>Age</b><br>≥18 Years | <b>Healthy Volunteers</b><br>No |
|----------------------|-------------------------|---------------------------------|